Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline

Perspective Therapeutics, Inc.

Updated presentation includes ASCO 2026 data for VMT-α-NET in neuroendocrine tumors with 68 patients treated.
VMT01 for melanoma shows preliminary anti-tumor activity at 3.0 mCi dose in ongoing Phase 1/2a.
PSV359 targeting FAP-α for solid tumors is in Phase 1/2a with improved tumor retention.
Company emphasizes 212Pb-based theranostic approach and direct-to-hospital delivery model.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.